AbbVie is a U.S. biopharmaceutical company focused on discovering and delivering innovative medicines and solutions. It develops therapies across major disease areas and serves patients globally.
AbbVie will present new lung cancer data at WCLC 2026, including Phase 1b results for ABBV-1480 showing high response rates in NSCLC and safety updates for ABBV-706 in SCLC. The company also reported progress in dermatology, obesity, and Crohn's disease programs.
Several drugmakers saw shares fall after earnings missed expectations. Alnylam's Amvuttra sales disappointed despite growth; Neurocrine's guidance underwhelmed; AbbVie's Imbruvica and Roche's Vabysmo fell short of consensus.
Biotech companies posted Q2 2026 results: REGENXBIO's Duchenne trial met its primary endpoint, Compass Pathways' COMP360 NDA submission is on track for Q4, Puma raised full-year guidance on NERLYNX demand, and Evotec cut its 2026 outlook.
A global investment firm agreed to acquire a medical device maker for $5.7 billion, while Juvisé Pharmaceuticals secured a $652 million refinancing and Pharmacelera raised $7.1 million. A biotech company also completed a $289 million IPO, and the MHRA issued AI guidance.
FDA final guidance sets standards for psychedelic clinical trials. Federal agencies and states are advancing psilocybin and ibogaine research, and Eli Lilly is acquiring AtaiBeckley for $2.8 billion.
AbbVie's Q2 2026 revenue hit $16.99 billion, beating estimates, but full-year EPS guidance was cut to $13.97. Growth in immunology and neuroscience continued, and the FAST study on ubrogepant wrapped up.
Revolution Medicines (RVMD) shares up 132% YTD. Daraxonrasib beat chemo in pancreatic cancer (13.2 vs 6.7 months median OS). Company has no marketed products and a $39B valuation.
West Pharmaceutical Services beat Q2 estimates with revenue of $872.3 million and raised full-year guidance, driven by GLP-1 and high-value product demand. The stock is up 32.9% year to date, and Wolfe Research upgraded the shares to Outperform with a $375 price target.
AbbVie posted record 2025 revenue of $61.2 billion and raised 2026 guidance on Skyrizi and Rinvoq growth. Pipeline advances include Crohn's submissions, obesity data, and European approval for Boey.
Lawmakers opened national security probes into Merck, AbbVie and others over China drug trials. A survey finds China closing in on U.S. biotech leadership, and HHS launched clinical trial reforms to counter the rise.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07772492 |
A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata |
RECRUITING | PHASE3 |
| NCT07771400 |
Molecular Ovarian Cancer Assessment in LatiNoAmerican PAtients |
NOT_YET_RECRUITING | |
| NCT07769502 |
A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers |
NOT_YET_RECRUITING | PHASE2 |
| NCT07756645 |
A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants |
NOT_YET_RECRUITING | PHASE3 |
| NCT07756580 |
A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of Glabellar Lines |
NOT_YET_RECRUITING | PHASE1 |
| NCT07752979 |
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities |
NOT_YET_RECRUITING | PHASE2 |
| NCT07744126 |
A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07741838 |
Effectiveness of Upadacitinib and Biologics for the Achievement of Minimal Disease Activity in Adults With Moderate-to-Severe Atopic Dermatitis (RAMpUp) |
NOT_YET_RECRUITING | |
| NCT07738887 |
Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations |
NOT_YET_RECRUITING | PHASE2 |
| NCT07736638 |
A Study to Assess the Safety, Tolerability and How Single Ascending Doses of ABBV-859 Moves Through the Body of Healthy Adult Participants |
RECRUITING | PHASE1 |
